RE:RE:RE:RE:Preservative free dry powder oat beta glucan..."Of the dozens of potential products they might accomplish including those mentioned just today Ceapro in its entire history has commercialized exactly ZERO"
Bottom Line: CZO has NEVER been stronger:
1) With sales lagging last year's blowout first half by one quarter(news release) and record inventory on standby a fresh three year deal with giant Symrise has been signed "further seruring a strong foundation for the future" as Symrise looks to make the deal "equally successful" in creating value: Timothy Kenny, Global President Cosmetic Ingredients, Symrise AG: “We believe this renewed commitment is an important milestone in our continued collaboration and this agreement further secures a strong foundation for the future. We are equally looking forward to making it successful in creating value.” news release The deal with Symrise has been expanded to include development of a preservative free oat beta glucan powder that has already been worked on for some months according to the news release. This happens after recent data from the Angiogenesis Foundation supporting CZO's oat beta glucan for wound healing. Gilles called the data a 'home run'. Dr. Li also expressed his excitement for numerous potential applications even using the words 'Intel Inside' in an analogy.
PGX has been the drying technology CZO historically hoped to use to create a powder, preservative free oat beta glucan. With PGX now being scaled-up is this new deal with Symrise a secretive PGX deal? About PGX: "Benefits for the existing personal care market include being able to make preservative free product, an increase in shelf life, and a 98% reduction in shipping weights and associated greenhouse gasses by removing the water. A dry formulation would also allow Ceapro to pursue the large nutraceutical and functional food/drink markets where oat beta glucan has a well known health claim for cholesterol reduction. Unfortunately current standard drying technologies like spray drying or freeze drying are not feasible options for oat beta glucan, as well as many other biopolymers. A new technology was then needed, and that new technology is PGX." CZO 2014 news release
2) CZO's avenanthramide pill is expected to begin recruitment/enrollment in mid-November. The FDA recently approved its first, precedent setting treatment for inflammation and heart disease. The Principle Investigator working on CZO's clinical trial at the Montreal Heart Institute was important in the studies of the recently FDA approved drug and is an opinion leader on inflammation and heart disease globally.
Gilles notes that CZO will be focused on COVID's affect on the heart. Data concerning COVID and heart is becoming increasingly devastating: "The British Heart Foundation (BHF) said ongoing disruption to the NHS and the fallout from Covid has left the country is in the 'grip of a heart and stroke care emergency'." 100k more Brits have died 'of heart attacks and strokes since Covid' (msn.com) The recent wound healing data could support CZO's treatment, etc. Dr. William Li is a noted authority on blood vessels and had predicted a potential tsumani of heart disease in the Washington Post with a former FDA Commissioner eary in the pandemic after a study Dr. Li helped conduct that was published in the New England Journal Of Medicine.
3) CZO expects a 5-fold scale-up of PGX to be commissioned in the next approximately 6 months. Commissioning of a 10-fold scale-up of the current pilot plant is expected in Q3. A VP of Operations has been hired and put in charge of scale-up
4) CZO's CoQ10 bioavailability results released last October were a blow-out vs. the industry gold standard. Gilles has noted talks with serious potential partners have commenced and that they understand bioavailability as a unique selling point.
5) Oat flour: "
Successfully achieved the malting procedure for a first batch at small commercial scale level. Obtention of batch-to-batch consistency should allow for the offer of enriched formulations with high concentration of avenanthramides to serve some nutraceutical markets." 6) Wound healing: "
These unprecedented results will not only support additional claims for commercially available formulations using Ceapro’s oat-based products but should also trigger interest from medical supply companies."
7) The US is considering reclassifying cannabis. The Department of Heath and Human Services has recommended reclassifying it to a Schedule III drug.
8) Fibrosis: "If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University." 9) CZO has materially strengthened its organization. The former head of Roche Canada, Ronnie Miller, became a Director and then Chariman. A Director has been added with experience in transactions and joint ventures. A CRO has been added and has developed a five year strategic plan. CZO has hired a VP of Technical Opeations in charge of PGX scale-up.
10) "Ongoing strategic corporate discussions progressing and continued planning for uplisting to Nasdaq" news release